CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00114-07v1
14/10/1307    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, M. L.
Right arrow Articles by Barnard, R. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, M. L.
Right arrow Articles by Barnard, R. T.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, October 2007, p. 1307-1310, Vol. 14, No. 10
1071-412X/07/$08.00+0     doi:10.1128/CVI.00114-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Use of Chimeric Antibodies as Positive Controls in an Enzyme-Linked Immunosorbent Assay for Diagnosis of Scrub Typhus (Infection by Orientia tsutsugamushi){triangledown}

Martina L. Jones* and Ross T. Barnard

School of Molecular and Microbial Sciences, University of Queensland, St. Lucia 4072, QLD, Australia

Received 9 March 2007/ Returned for modification 15 May 2007/ Accepted 30 July 2007

The use of human sera collected from individuals of known infected and noninfected status is necessary for the validation of diagnostic assays and for the determination of cutoff values. However, the routine inclusion of pooled human sera from infected individuals for use as positive controls in commercial assay kits has many disadvantages. Sufficient quantities of sera can be difficult to obtain, and there are ethical and safety issues to be considered. Additionally, each batch of control material requires standardization, as each will differ in antibody titer. We have genetically engineered chimeric immunoglobulin G (IgG), IgM, and IgA antibodies consisting of mouse-derived variable regions and human constant regions derived from peripheral blood lymphocytes. The chimeric nature of these antibodies allows the desired antigen specificity created through mouse immunization and hybridoma technology while retaining a human constant region required for recognition by the enzyme-conjugated antihuman signal antibody. We have investigated the potential use of chimeric IgG with specificity for the major surface antigen of Orientia tsutsugamushi as an alternative positive control for inclusion in a commercial enzyme-linked immunosorbent assay kit for the diagnosis of rickettsia scrub typhus (caused by infection with O. tsutsugamushi). Chimeric IgG was expressed in stably transfected CHO cells, allowing production of unlimited quantities. The purified protein was found to have a much greater specificity for the scrub typhus antigen than the serum-derived controls. The methods described could be applied to other assay kits for the detection of antibodies against infectious agents.


* Corresponding author. Mailing address: School of Molecular and Microbial Sciences, University of Queensland, St. Lucia 4072, QLD, Australia. Phone: 61 7 3365 4635. Fax: 61 7 3365 4699. E-mail: martina.jones{at}uq.edu.au

{triangledown} Published ahead of print on 8 August 2007.


Clinical and Vaccine Immunology, October 2007, p. 1307-1310, Vol. 14, No. 10
1071-412X/07/$08.00+0     doi:10.1128/CVI.00114-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.